Inceptionr LLC Takes $468,000 Position in Glaukos Corporation $GKOS

Inceptionr LLC acquired a new position in shares of Glaukos Corporation (NYSE:GKOS) during the first quarter, Holdings Channel.com reports. The fund acquired 4,348 shares of the medical instruments supplier’s stock, valued at approximately $468,000.

Several other large investors have also added to or reduced their stakes in GKOS. Janus Henderson Group PLC grew its holdings in Glaukos by 183.4% during the 4th quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after buying an additional 1,953,578 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after buying an additional 1,123,140 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Glaukos by 209.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock valued at $152,476,000 after acquiring an additional 913,458 shares during the period. Millennium Management LLC boosted its position in shares of Glaukos by 75.3% in the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock valued at $181,751,000 after acquiring an additional 691,289 shares during the period. Finally, UBS Group AG increased its holdings in Glaukos by 316.0% during the 4th quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock worth $98,677,000 after acquiring an additional 663,849 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Down 0.1%

NYSE GKOS opened at $153.40 on Monday. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.53. The firm has a market cap of $9.01 billion, a PE ratio of -46.77 and a beta of 0.75. The stock has a 50-day moving average of $135.85 and a 200-day moving average of $123.52.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm’s revenue was up 41.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. As a group, sell-side analysts forecast that Glaukos Corporation will post -0.57 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $140.00, for a total value of $1,400,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,681 shares in the company, valued at approximately $6,115,340. This represents a 18.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 1,700 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the sale, the director directly owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,273 shares of company stock worth $8,882,003 in the last ninety days. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on GKOS shares. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. HC Wainwright assumed coverage on Glaukos in a research note on Monday, July 6th. They set a “buy” rating and a $168.00 price objective for the company. Stifel Nicolaus upped their target price on Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, Citigroup upped their price objective on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.85.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.